Investing

Tarsus Pharmaceuticals : TARS

TARS

Stock Data

$63.62

$0.01 (0.02%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Tarsus Pharmaceuticals is a pioneering biopharmaceutical company based in Irvine, California, dedicated to developing innovative treatments for eye care. Its flagship product, XDEMVY, targets the treatment of blepharitis from Demodex mites and meibomian gland disease. Beyond eye care, Tarsus is expanding its reach into dermatology and infectious disease prevention, with products like TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and malaria reduction. Founded in 2016, Tarsus is committed to addressing unmet medical needs in various therapeutic areas.

All Tarsus Pharmaceuticals Articles

1 Article

Will Ashworth | Jan 27, 2025 at 11:53 AM EST

QQQ Crash: Live Updates on Amazon (AMZN), Meta, Apple (AAPL) Following Today’s Selloff 

Live Updates DeepSeek Isn’t the Only Reason for a Big Drop in Tech Stocks Jan 27, 2025 at 2:06 PM…